Given that loss-of-function SLC5A2 variants cause glucosuria and pharmacologic induction of glucosuria via SGLT2 inhibition is used to treat diabetes, we hypothesized that SLC5A2 variants will reduce the risk of diabetes. This evidence concerns the gene SLC5A2 and Glycosuria.